The week in health tech, explained in plain English.Get the free newsletter →
November 8, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Finance

AstraZeneca GLP-1 Pill Shows Promise in Obesity Trials

AstraZeneca's experimental GLP-1 pill posted encouraging results in mid-stage obesity and diabetes trials, STAT News reports, putting the drugmaker on a path to compete in one of the most lucrative markets in medicine. The data suggest the oral treatment can meaningfully address both weight and blood sugar, though it is still early to judge how it measures against established options.

The race centers on convenience. Most GLP-1 blockbusters, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound, are injectables. A pill that matches their effect could expand access, ease manufacturing constraints, and appeal to patients wary of needles. Lilly's oral orforglipron and Novo's oral options are also advancing, so AstraZeneca enters a crowded field.

For now, the key unknown is comparative efficacy and tolerability. STAT News notes it remains unclear how AstraZeneca's candidate stacks up against other oral treatments, and mid-stage results do not guarantee late-stage success. Larger trials will determine whether the company can carve out share in a market analysts expect to exceed $100 billion.

Sources

More in Finance

Finance

Novartis Lp(a) Drug Lowers Risk Marker but Fails on Outcomes

Novartis's pelacarsen lowered the cardiovascular risk marker Lp(a) but failed to reduce heart attacks or strokes, undermining a major industry strategy.

Why it matters: A failed outcomes trial for a leading Lp(a) drug threatens billions in cardiovascular research built on the assumption that lowering the marker prevents events.

Finance

Novo's Ziltivekimab Flops, But Cardiologists Stay Bullish

Novo Nordisk's ziltivekimab missed in the ZEUS cardiovascular trial, but cardiologists say the anti-inflammatory approach to heart disease remains valid.

Why it matters: Anti-inflammatory therapy is one of the biggest bets in cardiovascular medicine, and how the field reacts to a high-profile failure shapes billions in future R&D.

Finance

Pennsylvania Revokes Sharon Regional Hospital License

Pennsylvania revoked Sharon Regional Medical Center's license and ordered it to close after its utility moved to cut power over an unpaid bill.

Why it matters: An unpaid electricity bill forcing a hospital's closure shows how severe financial distress can abruptly cut off care for an entire community.